IRulya Therapeutics Inc.（IRLA）财务数据IRLAIRulya Therapeutics Inc.

In the context of the broader market, IRLA competes directly with industry leaders such as IMMP and IXHL. With a market capitalization of $31.72M, it holds a leading position in the sector. When comparing efficiency, IRLA's gross margin of N/A stands against IMMP's 100.00% and IXHL's N/A. Such benchmarking helps identify whether IRulya Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown consistent net income losses, with a projected loss of -75,488,000 for Q2 2026. Its gross profit has been negligible, and the current ratio has declined significantly, indicating potential liquidity problems.